Key features and details
- One-wash 90 minute protocol
- Sensitivity: 69.68 pg/ml
- Range: 156.25 pg/ml - 10000 pg/ml
- Sample type: Cit plasma, EDTA Plasma, Serum
- Detection method: Colorimetric
- Assay type: Sandwich (quantitative)
- Reacts with: Human
Product nameHuman GHR ELISA Kit (Growth Hormone Receptor)
See all Growth hormone receptor kits
Intra-assay Sample n Mean SD CV% Serum 8 4.8% Inter-assay Sample n Mean SD CV% Serum 3 3.7%
Sample typeSerum, EDTA Plasma, Cit plasma
Assay typeSandwich (quantitative)
Range156.25 pg/ml - 10000 pg/ml
Sample specific recovery Sample type Average % Range Serum 106 97% - 112% EDTA Plasma 115 107% - 121% Cit plasma 101 100% - 103%
Assay time1h 30m
Assay durationOne step assay
Species reactivityReacts with: Human
Does not react with: Cow
Human GHR ELISA Kit (Growth Hormone Receptor) (ab260060) is a single-wash 90 min sandwich ELISA designed for the quantitative measurement of GHR (Growth Hormone Receptor) protein in cit plasma, edta plasma, and serum. It uses our proprietary SimpleStep ELISA® technology. Quantitate Human GHR (Growth Hormone Receptor) with 69.68 pg/ml sensitivity.
SimpleStep ELISA® technology employs capture antibodies conjugated to an affinity tag that is recognized by the monoclonal antibody used to coat our SimpleStep ELISA® plates. This approach to sandwich ELISA allows the formation of the antibody-analyte sandwich complex in a single step, significantly reducing assay time. See the SimpleStep ELISA® protocol summary in the image section for further details. Our SimpleStep ELISA® technology provides several benefits:
- Single-wash protocol reduces assay time to 90 minutes or less
- High sensitivity, specificity and reproducibility from superior antibodies
- Fully validated in biological samples
- 96-wells plate breakable into 12 x 8 wells strips
A 384-well SimpleStep ELISA® microplate (ab203359) is available to use as an alternative to the 96-well microplate provided with SimpleStep ELISA® kits.
Human Growth Hormone Receptor (GHR) is a receptor protein that binds pituitary gland growth hormone involved in regulating postnatal body growth. Human GHR cDNA encodes a 638 amino acid (aa) residue type I transmembrane protein with an 18 aa putative signal peptide, a 246 aa extracellular domain, a 24 aa transmembrane domain and a 350 aa cytoplasmic domain. At least two alternatively spliced isoforms of human GHR, lacking the sequence encoded by exon 3, or lacking most of the cytoplasmic domain, also exist. Soluble GH-binding proteins corresponding to extracellular domain of the transmembrane proteins can be generated from the membrane proteins. Ligation of GHR by GH results in receptor dimerization and activation of the JAK/STAT signaling cascade. The soluble GHBP has been shown to interfere with GH signaling by competing with the transmembrane receptor of GH. Alternatively, the GHBP has also been shown to enhance GH action by slowing GH clearance. Human GHR shares 66%, 68%, 67%, and 94% sequence homology with mouse, rat, cow, and monkey respectively.
PlatformPre-coated microplate (12 x 8 well strips)
Storage instructionsStore at +4°C. Please refer to protocols.
Components 1 x 96 tests 10X Human GHR (Growth Hormone Receptor) Capture Antibody 1 x 600µl 10X Human GHR (Growth Hormone Receptor) Detector Antibody 1 x 600µl 10X Wash Buffer PT (ab206977) 1 x 20ml Antibody Diluent 4BI 1 x 6ml Human GHR (Growth Hormone Receptor) Lyophilized Recombinant Protein 2 vials Plate Seals 1 unit Sample Diluent NS (ab193972) 1 x 50ml SimpleStep Pre-Coated 96-Well Microplate (ab206978) 1 unit Stop Solution 1 x 12ml TMB Development Solution 1 x 12ml
FunctionReceptor for pituitary gland growth hormone involved in regulating postnatal body growth. On ligand binding, couples to the JAK2/STAT5 pathway.
The soluble form (GHBP) acts as a reservoir of growth hormone in plasma and may be a modulator/inhibitor of GH signaling.
Isoform 2 up-regulates the production of GHBP and acts as a negative inhibitor of GH signaling.
Tissue specificityExpressed in various tissues with high expression in liver and skeletal muscle. Isoform 4 is predominantly expressed in kidney, bladder, adrenal gland and brain stem. Isoform 1 expression in placenta is predominant in chorion and decidua. Isoform 4 is highly expressed in placental villi. Isoform 2 is expressed in lung, stomach and muscle. Low levels in liver.
Involvement in diseaseDefects in GHR are a cause of Laron syndrome (LARS) [MIM:262500]. A severe form of growth hormone insensitivity characterized by growth impairment, short stature, dysfunctional growth hormone receptor, and failure to generate insulin-like growth factor I in response to growth hormone.
Defects in GHR may be a cause of idiopathic short stature autosomal (ISSA) [MIM:604271]. Short stature is defined by a subnormal rate of growth.
Sequence similaritiesBelongs to the type I cytokine receptor family. Type 1 subfamily.
Contains 1 fibronectin type-III domain.
DomainThe WSXWS motif appears to be necessary for proper protein folding and thereby efficient intracellular transport and cell-surface receptor binding.
The box 1 motif is required for JAK interaction and/or activation.
The extracellular domain is the ligand-binding domain representing the growth hormone-binding protein (GHBP).
The ubiquitination-dependent endocytosis motif (UbE) is required for recruitment of the ubiquitin conjugation system on to the receptor and for its internalization.
modificationsThe soluble form (GHBP) is produced by phorbol ester-promoted proteolytic cleavage at the cell surface (shedding) by ADAM17/TACE. Shedding is inhibited by growth hormone (GH) binding to the receptor probably due to a conformational change in GHR rendering the receptor inaccessible to ADAM17.
On GH binding, phosphorylated on tyrosine residues in the cytoplasmic domain by JAK2.
On ligand binding, ubiquitinated on lysine residues in the cytoplasmic domain. This ubiquitination is not sufficient for GHR internalization.
Cellular localizationSecreted; Cell membrane. On growth hormone binding, GHR is ubiquitinated, internalized, down-regulated and transported into a degradative or non-degradative pathway and Cell membrane. Remains fixed to the cell membrane and is not internalized.
- Information by UniProt
- GH receptor
- GH-binding protein
SimpleStep ELISA technology allows the formation of the antibody-antigen complex in one single step, reducing assay time to 90 minutes. Add samples or standards and antibody mix to wells all at once, incubate, wash, and add your final substrate. See protocol for a detailed step-by-step guide.
The GHR standard curve was prepared as described in Section 10. Raw data values are shown in the table. Background-subtracted data values (mean +/- SD) are graphed.
The concentrations of GHR were measured in duplicates, interpolated from the GHR standard curves and corrected for sample dilution. Undiluted samples are as follows: serum 25%, plasma (citrate) 25%, and plasma (EDTA) 25%. The interpolated dilution factor corrected values are plotted (mean +/- SD, n=2). The mean GHR concentration was determined to be 31.76 ng/mL in serum, 31.76 ng/mL in plasma (citrate), and 21.28 ng/mL in plasma (EDTA).
To learn more about the advantages of recombinant antibodies see here.
ab260060 has not yet been referenced specifically in any publications.